Caribou Biosciences, Inc.
CRBU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.02 | -0.05 | -0.38 |
| FCF Yield | -11.64% | -24.46% | -44.63% | -25.06% |
| EV / EBITDA | -8.61 | -3.44 | -1.95 | -4.15 |
| Quality | ||||
| ROIC | -17.33% | -24.49% | -17.37% | -13.68% |
| Gross Margin | 71.29% | 100.00% | 100.00% | -1,337.84% |
| Cash Conversion Ratio | 0.91 | 0.52 | 0.92 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -35.48% | -13.82% | -12.27% | -10.31% |
| Free Cash Flow Growth | 11.77% | 24.07% | -4.94% | -7.96% |
| Safety | ||||
| Net Debt / EBITDA | -0.53 | -0.02 | 0.08 | -0.27 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -457.81 | 93.81 | 104.80 | 133.41 |